Development of porphyrin and titanium dioxide sonosensitizers for sonodynamic cancer therapy

Xiangyu Deng; Zengwu Shao; Yanli Zhao

doi:10.3877/cma.j.issn.2096-112X.2021.01.009

Development of porphyrin and titanium dioxide sonosensitizers for sonodynamic cancer therapy

Biomater Transl. 2021 Mar 28;2(1):72-85. doi: 10.3877/cma.j.issn.2096-112X.2021.01.009. eCollection 2021.

Authors

Xiangyu Deng^{1

2}, Zengwu Shao¹, Yanli Zhao²

Affiliations

¹ Department of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
² Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, Singapore.

PMID: 35837259
PMCID: PMC9255825
DOI: 10.3877/cma.j.issn.2096-112X.2021.01.009

Abstract

Sonodynamic therapy for malignant tumours has gained much attention for its deep penetration effect and efficient tumour killing ability. The design, modification, and utilization of sonosensitizers are important aspects of sonodynamic therapy. As an essential factor in this process, highly effective sonosensitizers should be developed to facilitate the clinical applications of sonodynamic therapy. This review takes porphyrin- and titanium dioxide (TiO₂)-based systems as representative organic and inorganic sonosensitizers respectively, and summarizes their characteristics and biological effects as sonodynamic therapy. Upon discovery of novel sonosensitizers, sonodynamic therapy becomes an efficient means of adjuvant therapy for the treatment of malignant tumours.

Keywords: TiO2; cancer treatment; porphyrins; sonodynamic therapy; sonosensitizers.

Publication types

Review

Grants and funding

This work was supported by the National Key Research and Development Program of China (No. 2016YFC1100100), and the Singapore National Research Foundation Investigatorship (No. NRF-NRFI2018-03).